Fetroja
(Cefiderocol)ApprovedSmall molecule
ShionogiFetroja is one of 74 small molecule programs targeting Gram-Negative Bacterial Infections. It is currently in Approved.
5
Indications
19
Total Trials
4
Active Trials
73
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
105 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Fetroja
ShionogiApproved
Ibsrela
AArdelyx
Phase 3
Biaxin
AbbViePhase 2
Lamprene
NovartisPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Sirturo
WWim Janssens
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pediatric2 trials
Gram-Negative Bacterial Infections1 trial
Urinary Tract Infection1 trial
13 more indications
Bacterial Infections1 trial
Infants1 trial
Pneumonia1 trial
Renal Replacement Therapy1 trial
Severe Infection1 trial
Midazolam1 trial
Bacterial Pneumonia1 trial
Ampicillin1 trial
Liver1 trial
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial
Not yet recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 3·NCT07759453·168 enrolled
Regulatory
FDA Approval Timeline[4]
Nov 14, 2019
FETROJA
NDA NDA209445
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefiderocol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]